Loading...
OTCM
VRAYQ
Market cap479mUSD
Nov 03, Last price  
0.00
Name

ViewRay Inc

Chart & performance

D1W1MN
OTCM:VRAYQ chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
25.32%
Rev. gr., 5y
24.59%
Revenues
102m
+45.76%
1,854,0003,159,0000010,390,00022,237,00034,042,00080,962,00087,782,00057,017,00070,119,000102,206,000
Net income
-107m
L-2.47%
-19,707,000-27,222,00000-44,995,000-50,636,000-72,176,000-76,396,000-120,199,000-107,908,000-110,048,000-107,330,000
CFO
-92m
L+47.70%
-18,866,000-25,371,000-27,469,000-39,849,000-28,156,000-70,053,000-122,194,000-79,567,000-63,474,000-62,091,000-91,708,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ViewRay, Inc. specializes in the development, production, and global distribution of advanced magnetic resonance imaging (MRI)-guided radiation therapy systems, which are utilized for both diagnosing and treating cancer patients. These systems are deployed across multiple international regions, including the United States, France, Taiwan, and the United Kingdom. The company's primary offering is MRIdian, an innovative MRI-guided radiation therapy solution specifically designed to mitigate common issues such as beam distortion and skin toxicity. ViewRay caters to a wide array of clients, ranging from academic and research hospitals to local community hospitals, private medical clinics, governmental healthcare providers, and independent cancer care facilities. The distribution of its MRIdian system is handled through a combination of a dedicated direct sales team and an extensive partner network. Established in 2004, ViewRay, Inc. has its corporate headquarters situated in Oakwood, Ohio.

Key people

Paul Ziegler
President, Chief Executive Officer · since 2023
Cassie Mahar
Interim Chief Financial Officer · since 2023
Adam Podbelski
Senior Vice President- Commercial Operations · since 2023
James Dempsey
Chief Scientific Officer · since 2020
Caley Castelein
Independent Director · since 2008
Independent Director · since 2020
Independent Chairman of the Board · since 2018
Independent Director · since 2021
Independent Director · since 2015
IPO date
Nov 04, 2014
Employees
295
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT